dipyridamole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
924 58-32-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dipyridamole
  • cardoxil
  • cardoxin
  • cleridium
  • dipyridamine
  • dipyridamol
  • dipyridan
  • peridamol
  • persantin
  • stenocardil
  • stimolcardio
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
  • Molecular weight: 504.64
  • Formula: C24H40N8O4
  • CLOGP: 2.21
  • LIPINSKI: 2
  • HAC: 12
  • HDO: 4
  • TPSA: 145.44
  • ALOGS: -2.74
  • ROTB: 12
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.20 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.21 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.82 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 13 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.154 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 13.032 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 23.442 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 29.648 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 4.260 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 17.220 % High 1
herg hERG pIC50 5.028 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 17.742 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 85.310 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 3.400 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AURKB,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK19,CDK3,CDK5,CDK7,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,MAP3K21,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PAK4,PDK2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 40
kinase-selectivity-class BRAF,CDK16,MAP3K21,MAPK11,PRKDC 5
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 3.802 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 21.478 High 1
mh-clint Mouse hepatocyte intrinsic clearance 59.020 High 1
mppb Mouse plasma protein binding (% unbound) 2.810 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 45.920 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 10.600 % High 1
rat-kpuu-brain Rat brain Kpuu 0.006 % High 1
rh-clint Rat hepatocyte intrinsic clearance 144.544 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 22.300 % High 1
rppb Rat plasma protein binding (% unbound) 5.280 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 15.382 uM High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 6, 1961 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sedation complication 1531.36 29.46 357 9502 16587 90602001
Creatinine renal clearance decreased 1497.77 29.46 358 9501 18541 90600047
Blood calcium decreased 1340.83 29.46 360 9499 29822 90588766
Orthostatic hypotension 1264.36 29.46 369 9490 41458 90577130
Sedation 1191.50 29.46 364 9495 47807 90570781
Cognitive disorder 1111.88 29.46 377 9482 69030 90549558
Depressed level of consciousness 1067.08 29.46 370 9489 72414 90546174
Balance disorder 963.05 29.46 370 9489 96710 90521878
Constipation 605.07 29.46 376 9483 280019 90338569
Mobility decreased 599.19 29.46 359 9500 250375 90368213
Hypotension 561.04 29.46 379 9480 325018 90293570
Fall 507.10 29.46 417 9442 481393 90137195
Toxicity to various agents 490.24 29.46 333 9526 287513 90331075
Pain 201.26 29.46 374 9485 995967 89622621
Creatinine renal clearance increased 187.74 29.46 48 9811 3233 90615355
Renal function test abnormal 175.59 29.46 54 9805 7137 90611451
Multiple drug therapy 143.46 29.46 46 9813 6963 90611625
Drug ineffective 81.51 29.46 25 9834 1384273 89234315
Nail ridging 80.23 29.46 17 9842 498 90618090
Skin wrinkling 58.39 29.46 16 9843 1406 90617182
Drug interaction 50.47 29.46 100 9759 276353 90342235
Drug abuse 48.50 29.46 52 9807 82295 90536293
Nail discolouration 45.40 29.46 16 9843 3226 90615362
Abdominal discomfort 40.49 29.46 3 9856 477325 90141263
Bladder disorder 37.93 29.46 20 9839 10752 90607836
Joint swelling 37.91 29.46 5 9854 503295 90115293
Fatigue 36.82 29.46 43 9816 1153980 89464608
Weight increased 34.40 29.46 3 9856 417924 90200664
Electrocardiogram ST segment depression 34.02 29.46 13 9846 3290 90615298
Peripheral swelling 33.91 29.46 3 9856 413103 90205485
Circulatory collapse 33.29 29.46 25 9834 24879 90593709
Arthralgia 33.24 29.46 22 9837 778500 89840088
Overdose 31.12 29.46 59 9800 157650 90460938
Dementia 29.79 29.46 23 9836 23838 90594750

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Labelled drug-drug interaction medication error 39.63 19.53 23 4422 15559 42601331
Cerebral haemorrhage 38.19 19.53 32 4413 38934 42577956
Peritoneal haematoma 32.14 19.53 6 4439 94 42616796
Splenic injury 31.57 19.53 5 4440 27 42616863
Hypotension 28.09 19.53 74 4371 257557 42359333
Cerebrovascular accident 27.97 19.53 42 4403 97118 42519772
Vitreous haemorrhage 25.82 19.53 10 4435 2737 42614153
Gastrointestinal haemorrhage 24.98 19.53 40 4405 97686 42519204
Haemorrhage intracranial 23.06 19.53 17 4428 17175 42599715
Embolic stroke 22.99 19.53 11 4434 5029 42611861
Electric shock sensation 22.67 19.53 6 4439 482 42616408
Intra-abdominal haemorrhage 21.77 19.53 9 4436 2919 42613971
Abdominal sepsis 21.19 19.53 7 4438 1213 42615677
Monocytosis 19.90 19.53 6 4439 773 42616117
Bronchitis chronic 19.58 19.53 7 4438 1534 42615356

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sedation complication 1462.88 19.22 366 13688 19489 110555756
Creatinine renal clearance decreased 1418.86 19.22 364 13690 21451 110553794
Blood calcium decreased 1261.90 19.22 369 13685 35476 110539769
Orthostatic hypotension 1073.38 19.22 378 13676 65871 110509374
Cognitive disorder 1031.58 19.22 395 13659 87116 110488129
Sedation 1024.55 19.22 370 13684 69313 110505932
Depressed level of consciousness 909.50 19.22 387 13667 111891 110463354
Balance disorder 882.41 19.22 383 13671 116177 110459068
Mobility decreased 581.66 19.22 366 13688 237056 110338189
Constipation 500.08 19.22 391 13663 357395 110217850
Hypotension 493.48 19.22 456 13598 523393 110051852
Fall 406.58 19.22 438 13616 603044 109972201
Toxicity to various agents 323.38 19.22 349 13705 480206 110095039
Pain 197.62 19.22 397 13657 954558 109620687
Creatinine renal clearance increased 175.56 19.22 48 14006 3577 110571668
Renal function test abnormal 151.86 19.22 53 14001 8893 110566352
Multiple drug therapy 130.37 19.22 46 14008 7968 110567277
Nail ridging 75.64 19.22 17 14037 561 110574684
Drug ineffective 58.01 19.22 65 13989 1520475 109054770
Skin wrinkling 54.53 19.22 16 14038 1537 110573708
Drug interaction 53.47 19.22 162 13892 500021 110075224
Electrocardiogram ST segment depression 41.31 19.22 18 14036 5443 110569802
Nail discolouration 41.19 19.22 16 14038 3619 110571626
Peripheral swelling 39.91 19.22 3 14051 404031 110171214
Bladder disorder 39.79 19.22 22 14032 11115 110564130
Joint swelling 39.27 19.22 5 14049 442840 110132405
Fatigue 38.09 19.22 60 13994 1215898 109359347
Arthralgia 35.88 19.22 28 14026 779604 109795641
Abdominal discomfort 33.61 19.22 5 14049 393853 110181392
Cerebral haemorrhage 33.00 19.22 41 14013 64927 110510318
Weight increased 32.19 19.22 7 14047 419637 110155608
Product dose omission issue 30.11 19.22 3 14051 321779 110253466
Infusion related reaction 29.97 19.22 6 14048 381156 110194089
Dementia 28.43 19.22 27 14027 31646 110543599
Sinusitis 27.15 19.22 3 14051 296685 110278560
Cerebral infarction 26.79 19.22 33 14021 51805 110523440
Cerebrovascular accident 25.52 19.22 65 13989 181219 110394026
Musculoskeletal stiffness 25.18 19.22 3 14051 279819 110295426
Embolic stroke 25.16 19.22 15 14039 8728 110566517
Peripheral coldness 25.14 19.22 20 14034 18520 110556725
Peritoneal haematoma 25.06 19.22 6 14048 262 110574983
Circulatory collapse 23.24 19.22 28 14026 42965 110532280
Labelled drug-drug interaction medication error 22.61 19.22 23 14031 29279 110545966
Vitreous haemorrhage 21.83 19.22 11 14043 4609 110570636
Subdural haematoma 21.79 19.22 25 14029 36429 110538816
Stomatitis 21.78 19.22 4 14050 270238 110305007
Contraindicated product administered 21.52 19.22 3 14051 248264 110326981
COVID-19 21.15 19.22 3 14051 245057 110330188
Intraventricular haemorrhage 20.01 19.22 11 14043 5496 110569749
Systemic lupus erythematosus 19.99 19.22 4 14050 254334 110320911
Splenic injury 19.82 19.22 5 14049 272 110574973
Haemorrhage intracranial 19.26 19.22 21 14033 28948 110546297

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AC07 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Platelet aggregation inhibitors excl. heparin
FDA PE N0000008832 Decreased Platelet Aggregation
FDA EPC N0000175578 Platelet Aggregation Inhibitor
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006401 Hematologic Agents
MeSH PA D010726 Phosphodiesterase Inhibitors
MeSH PA D010975 Platelet Aggregation Inhibitors
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:50249 anticoagulant
CHEBI has role CHEBI:50427 platelet aggregation inhibitor
CHEBI has role CHEBI:50444 adenosine phosphodiesterase inhibitor
CHEBI has role CHEBI:50445 EC 3.5.4.4 (adenosine deaminase) inhibitor
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:75835 anti-anaemic agent

Related Drugs by ATC class:

B01AC Platelet aggregation inhibitors excl. heparin 24 drugs
abciximabacetylsalicylic acidaloxiprinberaprostcangrelorcarbasalate calciumcilostazolclopidogrelcloricromenditazoleepoprostenoleptifibatide show all 24 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic heart failure indication 48447003
Atrial fibrillation indication 49436004 DOID:0060224
Platelet Aggregation Inhibition indication
Prevention of Cerebral Thrombosis indication
Myocardial Perfusion Imaging Adjunct indication
Cerebral embolism off-label use 75543006 DOID:4372
Transient ischemic attack off-label use 266257000 DOID:224
Thromboembolic disorder off-label use 371039008
Myocardial Reinfarction Prevention off-label use
Alcoholism contraindication 7200002
Poisoning by digitalis glycoside contraindication 12876009
Peptic ulcer contraindication 13200003 DOID:750
Senile cardiac amyloidosis contraindication 16573007
Myocardial infarction contraindication 22298006 DOID:5844
Sick sinus syndrome contraindication 36083008 DOID:13884
Gastrointestinal ulcer contraindication 40845000
Myxedema contraindication 43153006 DOID:11634
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Sinus bradycardia contraindication 49710005
Myocarditis contraindication 50920009 DOID:820
Vitamin K deficiency contraindication 52675005 DOID:11249
Nasal polyp contraindication 52756005
Acute nephropathy contraindication 58574008
Hypercalcemia contraindication 66931009 DOID:12678
Ventricular fibrillation contraindication 71908006
Factor II deficiency contraindication 73975000
Reye's syndrome contraindication 74351001 DOID:14525
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Gastrointestinal hemorrhage contraindication 74474003
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Cor pulmonale contraindication 83291003 DOID:8515
Constrictive pericarditis contraindication 85598007 DOID:11481
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Hemophilia contraindication 90935002
Anemia due to enzyme deficiency contraindication 111577008
von Willebrand disorder contraindication 128105004 DOID:12531
Hypomagnesemia contraindication 190855004
Atrioventricular block contraindication 233917008 DOID:0050820
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Idiopathic hypertrophic subaortic stenosis contraindication 360465008
Acute coronary syndrome contraindication 394659003
Breastfeeding (mother) contraindication 413712001
Restrictive cardiomyopathy contraindication 415295002 DOID:397
Acute erosive gastritis contraindication 444926003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.0 Basic
pKa2 8.52 Basic
pKa3 2.75 Basic
pKa4 2.12 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Enzyme INHIBITOR Ki 6 CHEMBL CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4A Enzyme INHIBITOR IC50 5.80 DRUG MATRIX CHEMBL
Equilibrative nucleoside transporter 1 Transporter INHIBITOR Ki 8.50 CHEMBL CHEMBL
Phosphodiesterase 3 Enzyme INHIBITOR IC50 4.37 CHEMBL CHEMBL
Phosphodiesterase 7 Enzyme INHIBITOR Ki 6.22 CHEMBL CHEMBL
Phosphodiesterase 6 Enzyme INHIBITOR Ki 6.90 CHEMBL CHEMBL
Phosphodiesterase 1 Enzyme INHIBITOR IC50 4.35 CHEMBL CHEMBL
cGMP-specific 3',5'-cyclic phosphodiesterase Enzyme INHIBITOR IC50 6.28 CHEMBL CHEMBL
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B Enzyme INHIBITOR IC50 4.30 IUPHAR CHEMBL
cGMP-dependent 3',5'-cyclic phosphodiesterase Enzyme INHIBITOR IC50 5.49 CHEMBL CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 7B Enzyme INHIBITOR IC50 6 CHEMBL CHEMBL
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A Enzyme INHIBITOR IC50 5.10 CHEMBL CHEMBL
ATP-binding cassette sub-family G member 2 Transporter IC50 5.19 CHEMBL
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A Enzyme Ki 6.40 CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4D Enzyme IC50 5.55 CHEMBL
Equilibrative nucleoside transporter 4 Transporter INHIBITOR Ki 5.90 IUPHAR
Protein prune homolog Enzyme IC50 6.11 CHEMBL
Sodium/nucleoside cotransporter 1 Transporter INHIBITOR Ki 7.54 DRUG MATRIX
Replicase polyprotein 1ab Enzyme INHIBITOR IC50 6.26 SCIENTIFIC LITERATURE
Arachidonate 15-lipoxygenase Enzyme IC50 5.16 DRUG MATRIX
Cyclic nucleotide phosphodiesterase PDE3A Enzyme IC50 4.36 CHEMBL
Cyclic AMP-specific phosphodiesterase SSPDE4A1A Enzyme IC50 5.28 CHEMBL
ORF 73 Nuclear other AC50 5.05 CHEMBL

External reference:

IDSource
4017884 VUID
N0000146237 NUI
D00302 KEGG_DRUG
3521 RXNORM
4017884 VANDF
C0012582 UMLSCUI
CHEBI:4653 CHEBI
H9F PDB_CHEM_ID
CHEMBL932 ChEMBL_ID
D004176 MESH_DESCRIPTOR_UI
DB00975 DRUGBANK_ID
4807 IUPHAR_LIGAND_ID
1545 INN_ID
64ALC7F90C UNII
3108 PUBCHEM_CID
2527 MMSL
3353 MMSL
4619 MMSL
d00213 MMSL
000691 NDDF
387371005 SNOMEDCT_US
66859009 SNOMEDCT_US
64ALC7F90C INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 0115-1070 TABLET 25 mg ORAL ANDA 19 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 0115-1071 TABLET 50 mg ORAL ANDA 19 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 0115-1072 TABLET 75 mg ORAL ANDA 19 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 0404-9852 INJECTION 5 mg INTRAVENOUS ANDA 11 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 0404-9852 INJECTION 5 mg INTRAVENOUS ANDA 11 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 0641-2569 INJECTION 5 mg INTRAVENOUS ANDA 19 sections
Aspirin and Extended - Release Dipyridamole Capsules, 25 mg / 200 mg HUMAN PRESCRIPTION DRUG LABEL 2 0904-7056 CAPSULE 200 mg ORAL ANDA 21 sections
Aspirin and Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 2 16714-964 CAPSULE, EXTENDED RELEASE 200 mg ORAL ANDA 26 sections
Aggrenox HUMAN PRESCRIPTION DRUG LABEL 2 21695-656 CAPSULE 200 mg ORAL NDA 17 sections
Aspirin and Extended-Release Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 2 42291-116 CAPSULE 200 mg ORAL ANDA 26 sections
ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE HUMAN PRESCRIPTION DRUG LABEL 2 42571-274 CAPSULE, EXTENDED RELEASE 200 mg ORAL ANDA 26 sections
Aspirin and Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 2 43598-339 CAPSULE, EXTENDED RELEASE 200 mg ORAL ANDA 26 sections
Aspirin and Dipyridamole Extended Release Human Prescription Drug Label 2 47335-927 CAPSULE 200 mg ORAL ANDA 25 sections
Aspirin and Extended - Release Dipyridamole Capsules, 25 mg / 200 mg HUMAN PRESCRIPTION DRUG LABEL 2 49884-007 CAPSULE 200 mg ORAL ANDA 21 sections
DIPYRIDAMOLE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1447 INJECTION 5 mg INTRAVENOUS ANDA 11 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 51808-204 SOLUTION 5 mg INTRAVENOUS Unapproved drug other 7 sections
Aggrenox HUMAN PRESCRIPTION DRUG LABEL 2 54868-5143 CAPSULE 200 mg ORAL NDA 19 sections
ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE HUMAN PRESCRIPTION DRUG LABEL 2 63629-5045 CAPSULE, EXTENDED RELEASE 200 mg ORAL ANDA 26 sections
Aspirin and Extended-Release Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 2 65162-596 CAPSULE 200 mg ORAL ANDA 26 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 65841-662 TABLET, FILM COATED 25 mg ORAL ANDA 1 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 65841-663 TABLET, FILM COATED 50 mg ORAL ANDA 1 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 65841-664 TABLET, FILM COATED 75 mg ORAL ANDA 1 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 68151-2996 TABLET 25 mg ORAL NDA authorized generic 17 sections
Aggrenox HUMAN PRESCRIPTION DRUG LABEL 2 68151-3971 CAPSULE, EXTENDED RELEASE 200 mg ORAL NDA 19 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 68382-187 TABLET, FILM COATED 25 mg ORAL ANDA 18 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 68382-188 TABLET, FILM COATED 50 mg ORAL ANDA 18 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 68382-189 TABLET, FILM COATED 75 mg ORAL ANDA 18 sections
ASPRIN AND EXTENDED-RELEASE DIPYRIDAMOLE HUMAN PRESCRIPTION DRUG LABEL 2 68462-405 CAPSULE 200 mg ORAL ANDA 25 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 69584-181 TABLET, FILM COATED 25 mg ORAL ANDA 21 sections
Dipyridamole HUMAN PRESCRIPTION DRUG LABEL 1 69584-182 TABLET, FILM COATED 50 mg ORAL ANDA 21 sections